Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Recurrence × fludarabine phosphate × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 45 NIH 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8 Leukemia, Myeloid, Acute 7 Leukemia 5 Lymphoma 4 Leukemia, Biphenotypic, Acute 4 Myelodysplastic Syndromes 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Leukemia, B-Cell 2 Hodgkin Disease 2 Head and Neck Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Anemia, Refractory, with Excess of Blasts 2 Recurrence 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia, Myeloid, Chronic-Phase 1

Interventions

Dexamethasone 46 Cyclophosphamide 28 Lenalidomide 27 pomalidomide 24 Rituximab 23 venetoclax 22 fludarabine 21 Bortezomib 20 Paclitaxel 18 Gemcitabine 18 carfilzomib 16 Carboplatin 15 pembrolizumab 14 Cisplatin 14 daratumumab 13 Docetaxel 12 Calcium Dobesilate 12 Cytarabine 11 Azacitidine 11 obinutuzumab 10 Nivolumab 10 Bevacizumab 10 tisagenlecleucel 9 ibrutinib 9 durvalumab 8 blinatumomab 8 Injections 8 Cetuximab 8 zanubrutinib 7 selinexor 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04613557 2023-08-31

IMMUNICY-1

Celyad Oncology SA

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡